NEUROD1 is a transcriptional activator that binds to E-box DNA sequences and plays critical roles in defining molecular subtypes of neuroendocrine tumors. In small cell lung carcinoma (SCLC), NEUROD1 expression defines a distinct molecular subtype, with NEUROD1-dominant tumors representing approximately 17% of SCLC cases and exhibiting high neuroendocrine marker expression 1. NEUROD1 functions as part of a temporal evolution program in SCLC, where tumors can transition from ASCL1+ to NEUROD1+ states through MYC-driven reprogramming 2. The transcription factor regulates distinct genetic programs compared to ASCL1, including targeting MYC, and contributes to neuronal function pathways 3. NEUROD1 expression marks subtype plasticity in lung cancer, with KDM6A loss promoting ASCL1-to-NEUROD1 switching through epigenetic mechanisms 4. Beyond lung cancer, NEUROD1 is implicated in pancreatic cancer, where it defines the aberrantly differentiated endocrine exocrine (ADEX) subtype and regulates endocrine differentiation networks 5. In prostate cancer, NEUROD1 is expressed in neuroendocrine regions alongside ASCL1, though ASCL1 appears to be the dominant driver of neuroendocrine differentiation 6. These findings establish NEUROD1 as a key regulator of neuroendocrine cell fate specification across multiple cancer types.